Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA

Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA

Initiate Cue Biopharma (CUE) with a Buy rating on strong phase 2 CUE-221 CSU data vs Xolair, key 2026 catalysts, and risks—click to read now.

Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial

Cue Biopharma said Sunday its chronic hives candidate cleared a mid-stage trial, marking its first clinical data since its strategic pivot from cancer into immunology. In a Phase 2 China study in chronic spontaneous urticaria ...

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement